Table 4.

Clinical Follow-Up at 6 Months

	Shellac + Vitamin E–Based DCB (n = 39)	Iopromide-Based DCB (n = 39)
Major adverse cardiovascular events	3 (7.7)	4 (10.3)
Cardiac death	0	0
Myocardial infarction	1 (2.6)	1 (2.6)
Stent thrombosis	0	1 (2.6)
Target lesion revascularization	2 (5.1)	2 (5.1)
Target vessel revascularization	2 (5.1)	2 (5.1)
Stroke	0	0
New vessel revascularization	0	0

Values are n (%).

DCB = drug-coated balloon